Crystal structure of steroid reductase SRD5A reveals conserved steroid reduction mechanism

Abstract

Steroid hormones are essential in stress response, immune system regulation, and reproduction in mammals. Steroids with 3-oxo-Δ4 structure, such as testosterone or progesterone, are catalyzed by steroid 5α-reductases (SRD5As) to generate their corresponding 3-oxo-5α steroids, which are essential for multiple physiological and pathological processes. SRD5A2 is already a target of clinically relevant drugs. However, the detailed mechanism of SRD5A-mediated reduction remains elusive. Here we report the crystal structure of PbSRD5A from Proteobacteria bacterium, a homolog of both SRD5A1 and SRD5A2, in complex with the cofactor NADPH at 2.0 Å resolution. PbSRD5A exists as a monomer comprised of seven transmembrane segments (TMs). The TM1-4 enclose a hydrophobic substrate binding cavity, whereas TM5-7 coordinate cofactor NADPH through extensive hydrogen bonds network. Homology-based structural models of HsSRD5A1 and -2, together with biochemical characterization, define the substrate binding pocket of SRD5As, explain the properties of disease-related mutants and provide an important framework for further understanding of the mechanism of NADPH mediated steroids 3-oxo-Δ4 reduction. Based on these analyses, the design of therapeutic molecules targeting SRD5As with improved specificity and therapeutic efficacy would be possible.

LPCAT1 overexpression promotes the progression of hepatocellular carcinoma

“…HCC-derived SMMC-7721 and Huh7 cell lines were obtained from the Cell Bank of the Chinese Academy of Sciences, Shanghai, People’s Republic of China [ 24 ]. The cellular identity was confirmed by short tandem repeat profiles.…”

Inhibiting 3βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer

“… 2 Based on our knowledge of steroidal metabolism, we hypothesized that progesterone is converted to 5α-progesterone (5αP), 5β-progesterone (5βP), and the related downstream metabolites in patients ( Figure 4 A). 32 , 33 , 34 Pregnenolone, progesterone, and 5αP were used to treat LNCaP cells to confirm the progesterone metabolic pathway ( Figure S5 A). [ 3 H]-pregnenolone was used to treat fresh patient prostate biopsy samples ex vivo .…”

Molecular Characterization of Two Known SRD5A2 Gene Variants in Mexican Patients With Disorder of Sexual Development

“…Regarding p. Pro212Arg, the substitution is a change in a cyclic side chain amino acid (apolar) by a positively charged amino acid. The pathogenic variant led to structural destabilizing replacement (Figure 5) (Han et al, 2021). Therefore, the p.Pro212Arg/p.Glu197Asp pathogenic variants produce enzymes with impaired activity and are unable to catalyze the synthesis of DHT during embryogenesis, explaining the possible phenotypic alterations in patients with 46, XY DSD.…”